Home | About Us | Investor Relations | Products & Services | Science & Technology | People | News & Events | Contact Us News | Events

Search our site: 20 September 2004 Interim Report and Accounts for the six months ended 30 June 2004 Cyprotex PLC, a drug discovery technology and information company, today reports its interim results for the six months ended 30 June 2004. Highlights Turnover up by 140% at £886,000 (£369,000) Gross profit 185% higher at £734,000 (£257,000) Pre-tax loss over 22% lower at £832,000 (£1.08 million) Placing of £2.94 million (net of expenses) at beginning of period leaves cash balances at £2.7 million (£868,000) Customer portfolio expanded to 25 major companies including revenue generating contracts with Roche, AstraZeneca, Altana and Solvay Contractual discussions well advanced with further blue-chip pharmaceutical and biotechnology companies. Commenting on the results, Robert Atwater, Chairman of Cyprotex PLC, said: "Cyprotex has established a unique position in the world of drug discovery, and with our innovative approach and focus on further improving operational efficiencies remaining the same, management is now confident of achieving the financial goals it set itself at the start of 2004." Download Cyprotex Interim Report and Accounts For further information: Robert Morrisson Atwater, Chief Executive Officer Cyprotex plc Tel: +44 (0) 1625 505100 rmatwater@cyprotex.com www.cyprotex.com Media Enquires: Henry Harrison-Topham / Heather Salmond Abchurch Communications Tel: +44 (0) 20 7398 7700 heather.salmond@abchurch-group.com www.abchurch-group.com

News Contact: Robert Morrisson Atwater, Chairman & CEO +44 1625 505 152 ir@cyprotex.com Request an information pack: Name: Email address:

Legal Disclaimer